US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Oxford Biomedica PLC

11.26

0.0000

Volume:20.00

Turnover:223.82

Market Cap:1.36B

PE:-21.54

High:11.26

Open:11.26

Low:11.26

Close:11.26

52wk High:12.61

52wk Low:3.15

Shares:120.54M

Float Shares:63.00M

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5226

EPS(LYR):-0.5226

ROE:-75.20%

ROA:-7.44%

PB:30.38

PE(LYR):-21.54

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Oxford Biomedica PLC

Exchange:

PINK LIMITED

Establishment Date:

1996

Employees:

900

Office Location:

Windrush Court,Transport Way,Oxford,Oxfordshire,United Kingdom

Website:

- -

Zip Code:

OX4 6LT

Phone:

44 1865 783 000

Fax:

- -

Introduction:

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological malignancies and tumours; and OXB-401 that is in pre-clinical stage for the treatment of liver indication; as well as OXB-40X, OXB-40Y, and OXB-40Z, which are in pre-clinical stage for liver indication. The company has collaborations with Boehringer Ingelheim, Immatics, Arcellx, Orchard, and Beam Therapeutics; an agreement with Homology Medicines; license and clinical supply agreement with Juno Therapeutics, Inc.; and master services and development agreement with AstraZeneca UK Ltd and Serum Life Sciences Ltd. The company also has a strategic collaboration with Kite Pharma to develop and commercialize CART-ddBCMA, a lead late-stage product candidate. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OXBDF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"OXBDF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OXBDF\",,,,,undefined,":{"symbol":"OXBDF","market":"US","secType":"STK","nameCN":"Oxford Biomedica PLC","latestPrice":11.255,"timestamp":1770735559011,"preClose":11.255,"halted":0,"volume":20,"delay":15,"changeRate":0,"floatShares":63003965,"shares":120538820,"eps":-0.522632,"marketStatus":"Post-Mkt","change":0,"latestTime":"02-10 09:59:19 EST Delay","open":11.255,"high":11.255,"low":11.255,"amount":223.824,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.522632,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770771600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":11.255,"volumeRatio":0.002938},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OXBDF\",,,,,undefined,":{"symbol":"OXBDF","floatShares":63003965,"roa":"-7.44%","roe":"-75.20%","lyrEps":-0.522632,"volumeRatio":0.002938,"shares":120538820,"dividePrice":0,"high":11.255,"amplitude":0,"preClose":11.255,"low":11.255,"week52Low":3.15,"pbRate":"30.38","psRate":"6.58","week52High":12.61,"institutionHeld":0,"latestPrice":11.255,"eps":-0.522632,"divideRate":0,"volume":20,"delay":15,"ttmEps":-0.522632,"open":11.255,"prevYearClose":8.15,"prevWeekClose":11.192,"prevMonthClose":12.0325,"prevQuarterClose":8.15,"fiveDayClose":11.472,"twentyDayClose":9.985,"sixtyDayClose":8.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OXBDF\",params:#limit:5,,,undefined,":[{"date":"2024-04-29","symbol":"OXBDF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714377600000,"name":null,"time":"Pre-Market","dateTimestamp":1714363200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OXBDF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OXBDF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.4286,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4286,"analysts":7,"updateTime":1766120400000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":613227,"yearFounded":1996,"employeeNum":900,"address":"Windrush Court,Transport Way,Oxford,Oxfordshire,United Kingdom","zipCode":"OX4 6LT","officePhone":"44 1865 783 000"},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":-0.0913},{"period":"3month","weight":-0.2263},{"period":"6month","weight":-0.2881},{"period":"1year","weight":-0.3459},{"period":"ytd","weight":-0.2363}],"description":"Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological malignancies and tumours; and OXB-401 that is in pre-clinical stage for the treatment of liver indication; as well as OXB-40X, OXB-40Y, and OXB-40Z, which are in pre-clinical stage for liver indication. The company has collaborations with Boehringer Ingelheim, Immatics, Arcellx, Orchard, and Beam Therapeutics; an agreement with Homology Medicines; license and clinical supply agreement with Juno Therapeutics, Inc.; and master services and development agreement with AstraZeneca UK Ltd and Serum Life Sciences Ltd. The company also has a strategic collaboration with Kite Pharma to develop and commercialize CART-ddBCMA, a lead late-stage product candidate. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.","exchange":"PINK LIMITED","name":"Oxford Biomedica PLC","nameEN":"Oxford Biomedica PLC"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OXBDF\",market:\"US\",,,undefined,":null}}